20 completed, 4 not yet recruiting, 3 unknown, 2 recruiting. 31 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 31 | Completed 20, Not yet recruiting 4, Unknown 3, Recruiting 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Nematode Infections: new trials by email Literature Review of Nematode Infections trials Research Report on Nematode Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections emodepside (BAY 44-4400), Mebendazole 100 MG, similar placebo to mebendazole - Trichuris Trichiura; Infection, Hookworm Infection | Phase 3 | Not yet recruiting | Swiss Tropical & Public Health Institute | 315 | 2026-11-06 | 2026-08-14 |
| Combination Therapies for Trichuris Trichiura Infection in Schoolchildren in Honduras Placebo, Albendazole 400 mg, Albendazole Plus Ivermectin - Trichuriasis, Strongyloidiasis | Phase 3 | Not yet recruiting | Mundo Sano Foundation | 368 | 2026-11-01 | 2026-06-23 |
| Follow-up Assessment of Change in Soil-transmitted Helminths Infection Intensity in Uganda Albendazole 400mg, Ivermectin 3 mg - Ascariasis | Phase 3 | Not yet recruiting | Jennifer Keiser | 450 | 2026-10-01 | 2026-10-14 |
| Better Options for Lymphatic Filariasis Treatment MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole - Lymphatic Filariasis, Scabies | Phase 3 | Recruiting | Medicines Development for Global Health | 5100 | 2026-09-28 | 2026-10-07 |
| Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections emodepside (BAY 44-4400), matching placebo of emodepside, Mebendazole - Trichuris Trichiura; Infection, Hookworm Infection | Phase 3 | Completed | Swiss Tropical & Public Health Institute | 315 | 2025-11-25 | 2026-10-08 |
| Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness Pre-screening Phase, Screenig Phase, Randomization - Soil-Transmitted Helminths | Phase 3 | Recruiting | Insud Pharma | 20000 | 2025-09-01 | 2025-09-15 |
| 21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia Albendazole 400mg, Placebo - Loiasis With Positive Blood Microfilaremia, Loiasis | Phase 3 | Not yet recruiting | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 100 | 2025-01-15 | 2024-09-26 |
| A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects Levamisole 3 days, Levamisole 5 days, Placebo - Loiasis | Phase 2 / Phase 3 | Unknown | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 99 | 2024-06-21 | 2024-09-20 |
| Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, Placebo Moxidectin - Trichuriasis, Ascariasis | Phase 3 | Completed | Jennifer Keiser | 224 | 2024-05-14 | 2025-09-19 |
| Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura IVM (200 µg/kg) + ALB (400 mg), ALB (400mg) - Trichuriasis | Phase 3 | Completed | Jennifer Keiser | 161 | 2023-10-09 | 2024-04-10 |
| Efficacy and Safety of MOX/ALB Co-administration Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, Ivermectin 3 mg Oral Tablet - Trichuriasis, Ascariasis | Phase 3 | Completed | Jennifer Keiser | 255 | 2021-06-15 | 2024-01-24 |
| Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis Moxidectin, Ivermectin - Onchocerciasis | Phase 3 | Active not recruiting | Medicines Development for Global Health | 323 | 2021-05-03 | 2025-12-23 |
| Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole Moxidectin, Ivermectin, Albendazole - Onchocerciasis | Phase 3 | Completed | Medicines Development for Global Health | 12979 | 2021-05-03 | 2026-03-03 |
| Adjunctive Ivermectin Mass Drug Administration for Malaria Control Ivermectin, Placebo, Dihydroartemisinin-piperaquine - Malaria,Falciparum, Neglected Tropical Diseases | Phase 3 | Unknown | London School of Hygiene and Tropical Medicine | 24000 | 2021-05-03 | 2022-02-24 |
| Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration moxidectin (8 mg) / albendazole (400 mg), ivermectin (200 µg/kg) / albendazole (400 mg), ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL] - Trichuriasis, Ascariasis | Phase 2 / Phase 3 | Completed | Jennifer Keiser | 536 | 2021-03-01 | 2024-12-05 |
| Moxidectin for LF, Cote d'Ivoire (DOLF) Ivermectin, Diethylcarbamazine, Albendazole - Lymphatic Filariasis | Phase 3 | Completed | Washington University School of Medicine | 164 | 2020-08-20 | 2026-01-29 |
| A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India Doxycycline, Placebo - Lymphedema, Lymphatic Filariasis | Phase 3 | Completed | The Task Force for Global Health | 235 | 2019-01-15 | 2021-06-24 |
| Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Albendazole on Day 1, Ivermectin on Day 1, Diethylcarbamazine on day 1 - Trachoma, Yaws | Phase 3 | Completed | Lihir Medical Centre | 20000 | 2018-10-01 | 2019-02-28 |
| Efficacy and Safety of IVM/ALB Co-administration Albendazole, Albendazole and Ivermectin - Trichuriasis | Phase 2 / Phase 3 | Completed | Jennifer Keiser | 1673 | 2018-09-09 | 2024-03-20 |
| A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali Doxycycline, Placebo - Lymphedema, Lymphatic Filariasis | Phase 3 | Completed | The Task Force for Global Health | 220 | 2018-06-19 | 2021-06-24 |
Showing 20 of 31. Sign in to see all of them.
Elephantiasis, Filarial (8) · Trichuriasis (8) · Ancylostomiasis (7) · Hookworm Infections (7) · Onchocerciasis (7) · Strongyloidiasis (7) · Filariasis (6) · Ascariasis (5) · Lymphedema (3) · Scabies (3) · Enterobiasis (2) · Helminthiasis (2) · Loiasis (2) · Malaria (2) · Neglected Diseases (2)
Infections (31) · Parasitic Diseases (31) · Helminthiasis (29) · Secernentea Infections (29) · Spirurida Infections (16) · Filariasis (10) · Skin Diseases (10) · Skin Diseases, Infectious (10) · Skin Diseases, Parasitic (10) · Skin and Connective Tissue Diseases (10) · Hemic and Lymphatic Diseases (9) · Strongylida Infections (9) · Vector Borne Diseases (9) · Adenophorea Infections (8)
Albendazole (17) · Ivermectin (17) · moxidectin (7) · Doxycycline (3) · Tablets (3) · Albumins (2) · Bay 44-4400 (2) · Diethylcarbamazine (2) · Intravital Microscopy (2) · Mebendazole (2) · emodepside (2) · Azithromycin (1) · Levamisole (1) · Mass Drug Administration (1) · Random Allocation (1)
Jennifer Keiser (6) · Medicines Development for Global Health (4) · The Task Force for Global Health (3) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (2) · Swiss Tropical & Public Health Institute (2) · University Hospitals Cleveland Medical Center (2) · Albert Einstein College of Medicine (1) · Centro per le Malattie Tropicali (1) · Colorado State University (1) · Hospital de Niños R. Gutierrez de Buenos Aires (1) · Insud Pharma (1) · Lihir Medical Centre (1) · London School of Hygiene and Tropical Medicine (1) · Mahidol University (1) · Mundo Sano Foundation (1)
Côte d’Ivoire (4) · Ghana (4) · Tanzania (4) · Democratic Republic of the Congo (3) · India (2) · Sri Lanka (2) · Uganda (2) · United States (2) · Argentina (1) · Benin (1) · Burkina Faso (1) · Fiji (1) · Guinea-Bissau (1) · Honduras (1) · Italy (1)
Eric Ottesen, MD (3) · Benjamin Koudou, PhD (2) · Jennifer Keiser, Professor (2) · Tony Ukety, MD, DO, MPH (2) · Alejandro Javier Krolewiecki, PhD, MD (1) · Alejandro Krolewiecki, MD (1) · Anna R Last, MBChB PhD (1) · Brian D. Foy, PhD (1) · Catherine Bjerum, MD, MPH (1) · Christina M Coyle, MD (1) · Christopher L King, MD, PhD (1) · Gabriela Matamoros, PhD, MSc, BSc (1) · Hector Freilij, MD (1)
PMID 11873261, PMID 22610930, PMID 32228663, PMID 10656038, PMID 21572981, PMID 29346377, PMID 29361335, PMID 30878222, PMID 30885157, PMID 31558376, PMID 33137100, PMID 33930024, PMID 33979325, PMID 34191812, PMID 34226233, PMID 34281614, PMID 34403424, PMID 34632308, PMID 34856181, PMID 35217670, PMID 35476631, PMID 35701056, PMID 35803632, PMID 36354034, PMID 36461087, PMID 36897877, PMID 36917597, PMID 37036890, PMID 37357904, PMID 37419638, PMID 37616301, PMID 37721964, PMID 37899143, PMID 38175837, PMID 38319937, PMID 38517907, PMID 39242171, PMID 39380086, PMID 39551062, PMID 39591454, PMID 40345209, PMID 40615414, PMID 40675166, PMID 40752908, PMID 42264499, PMID 42684913, PMID 42848323
R01AI155739 (1)